Francis PT, Nordberg A, Arnold SE. A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease? Trends Pharmacol Sci 26: 104-111

Wolfson Centre for Age-Related Diseases, Guy's Campus, St Thomas Street, Kings College London, London SE1 1UL, UK.
Trends in Pharmacological Sciences (Impact Factor: 11.54). 03/2005; 26(2):104-11. DOI: 10.1016/
Source: PubMed


The prevalence of Alzheimer's disease (AD), a neurodegenerative condition whose greatest risk factor is old age, is expected to rise dramatically during the next five decades, along with the trend for increased longevity. Early diagnosis and intervention with therapies that halt or slow disease progress are likely to represent an important component of effective treatment. Although much progress has been made in this area, there are currently no clinically approved interventions for AD that are classed as disease modifying or neuroprotective. Cholinesterase inhibitors are a drug class used for the symptomatic treatment of AD. Recent evidence from preclinical studies indicates that these agents can attenuate neuronal damage and death from cytotoxic insults, and therefore might affect AD pathogenesis. The mechanisms by which these actions are mediated might or might not be directly related to their primary mode of action.

Download full-text


Available from: Agneta Nordberg, Oct 04, 2015
1 Follower
68 Reads
  • Source
    • "In case of 4aeg, different substituents are attached to triazolo[3,4- b][1] [3] [4]thiadiazine and among all of them 4g showed excellent inhibitory potential. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Nitrogen-containing heterocycles are of particular interest and significant importance for the discovery of potent bioactive agents in pharmaceutical industry. The present study reports the synthesis of a library of new conjugated heterocycles including 3,6-disubstituted-1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazoles (4a-g and 5a-e) and 3,6-disubstituted-1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazines (6a-h), by cyclocondensation reaction of 4-amino-5-(pyridin-4-yl)-4H-1,2,4-triazole-3-thiol 3 with various substituted aromatic acids and phenacyl bromides, respectively. The structures of newly synthesized compounds were characterized by elemental analysis, IR, (1)H and (13)C NMR spectroscopy and in case of 4c by X-ray crystallographic analysis. Newly synthesized triazolothiadiazoles and thiadiazines were screened for acetyl- and butyryl-cholinesterases and alkaline phosphatase inhibition. Almost all of the compounds showed good to excellent activities against acetylcholinesterase more than the reference drugs. Compound 5d exhibited IC50 value 0.77 ± 0.08 μM against acetylcholinesterase and 4a showed IC50 9.57 ± 1.42 μM against butyrylcholinesterase. Among all the tested compounds, 4a also proved as excellent inhibitor of alkaline phosphatase with IC50 0.92 ± 0.03 μM. These heteroaromatic hybrid structures were also tested for their anticancer activity against lung carcinoma (H157) and kidney fibroblast (BHK-21) cell lines and leishmanias. Variable cell growth inhibitory activities were obtained and many compounds exhibit potent %inhibition.
    European Journal of Medicinal Chemistry 03/2014; 78C:167-177. DOI:10.1016/j.ejmech.2014.03.046 · 3.45 Impact Factor
  • Source
    • "Experiments testing the efficacy of drugs in reversing the transient memory deficits caused by SD could thus provide reliable models in drug-discovery preclinical studies for the treatment of dementia-related cognitive decline. To date, treatments of AD and other dementias rely on the administration of anticholinesterase therapy (e.g., donepezil, rivastigmine, galantamine) or NMDA receptor antagonists (i.e., memantine) whose effects at a symptomatic (cognitive and behavioral) level and as neuroprotective agents are still under debate (Bullock, 2002; Francis et al., 2005). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Paradigms of sleep deprivation (SD) and memory testing in rodents (laboratory rats and mice) are here reviewed. The vast majority of these studies have been aimed at understanding the contribution of sleep to cognition, and in particular to memory. Relatively little attention, instead, has been devoted to SD as a challenge to induce a transient memory impairment, and therefore as a tool to test cognitive enhancers in drug discovery. Studies that have accurately described methodological aspects of the SD protocol are first reviewed, followed by procedures to investigate SD-induced impairment of learning and memory consolidation in order to propose SD protocols that could be employed as cognitive challenge. Thus, a platform of knowledge is provided for laboratory protocols that could be used to assess the efficacy of drugs designed to improve memory performance in rodents, including rodent models of neurodegenerative diseases that cause cognitive deficits, and Alzheimer's disease in particular. Issues in the interpretation of such preclinical data and their predictive value for clinical translation are also discussed.
    Frontiers in Systems Neuroscience 12/2013; 7:106. DOI:10.3389/fnsys.2013.00106
  • Source
    • "However, prolonged use of these drugs has also proven effective in slowing down or halting disease progression. In fact, several evidences from preclinical studies indicate that these compounds might rescue neuronal damage and death from beta-amyloid (Aß)-induced toxicity, thus interfering with AD pathogenesis.3 The exact mechanisms by which these effects are achieved remain to be elucidated although several reports suggest neuroprotective,4,5 anti-inflammatory,6–8 and antioxidant roles.9,10 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Alzheimer's disease, which is characterized by gradual cognitive decline associated with deterioration of daily living activities and behavioral disturbances throughout the course of the disease, is estimated to affect 27 million people around the world. It is expected that the illness will affect about 63 million people by 2030, and 114 million by 2050, worldwide. Current Alzheimer's disease medications may ease symptoms for a time but are not capable of slowing down disease progression. Indeed, all currently available therapies, such as cholinesterase inhibitors (donepezil, galantamine, rivastigmine), are primarily considered symptomatic therapies, although recent data also suggest possible disease-modifying effects. Gantenerumab is an investigational fully human anti-amyloid beta monoclonal antibody with a high capacity to bind and remove beta-amyloid plaques in the brain. This compound, currently undergoing Phase II and III clinical trials represents a promising agent with a disease-modifying potential in Alzheimer's disease. Here, we present an overview of gantenerumab ranging from preclinical studies to human clinical trials.
    Drug Design, Development and Therapy 11/2013; 7:1359-1364. DOI:10.2147/DDDT.S53401 · 3.03 Impact Factor
Show more